Thoracic General Hospital Of Athens I Sotiria

At Thoracic General Hospital Of Athens I Sotiria, the strongest research focus is on respiratory tract diseases and neoplasms, especially advanced non-small cell lung cancer, small cell lung cancer, and difficult-to-treat lung tumors with specific molecular features. These studies are designed to test new treatment approaches, compare them with existing care, and improve survival and disease control.

• Advanced and metastatic non-small cell lung cancer
• Small cell lung cancer and extensive-stage disease
• Stage III lung cancer not suitable for surgery
• Testing new targeted, immunotherapy, and combination treatment strategies

The site’s respiratory team is also studying biomarkers and treatment-response patterns to help identify which patients may benefit most from emerging therapies.

Clinical trials here also cover long-term respiratory diseases such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and pulmonary sarcoidosis. The main goal is to evaluate whether new therapies can reduce flare-ups, preserve lung function, and ease symptoms in people living with chronic, progressive lung conditions.

• COPD with frequent exacerbations
• Idiopathic pulmonary fibrosis
• Pulmonary sarcoidosis with or without extrapulmonary involvement
• Assessing symptom control, lung function, and longer-term safety

These studies reflect a strong interest in improving everyday disease management for patients with persistent respiratory inflammation and scarring.

The site is actively involved in virus diseases and bacterial infections and mycoses, with trials focused on COVID-19, severe community-acquired bacterial pneumonia, and other serious infections in hospitalized adults. Research in this area aims to improve recovery, refine treatment choices, and support better use of antibiotics and antiviral approaches.

• COVID-19 in hospitalized patients
• Severe community-acquired bacterial pneumonia
• Severe infections requiring hospital care
• Testing new infection treatments and improving diagnostic-guided care

Several studies are designed to help clinicians choose more effective therapies while reducing unnecessary broad-spectrum antibiotic use.

Research also extends into immune system diseases and digestive system diseases, including atopic dermatitis, Crohn’s disease, and ulcerative colitis. These trials are evaluating whether newer therapies can better control inflammation, improve quality of life, and provide safer long-term disease management.

• Atopic dermatitis
• Crohn’s disease
• Ulcerative colitis
• Comparing treatment effectiveness and long-term safety in chronic inflammatory disease

This area shows the hospital’s broader interest in immune-driven conditions beyond the lungs, with a focus on sustained control of relapsing disease.

In addition to respiratory and cancer research, the site is studying cardiovascular diseases, particularly heart failure with preserved or mildly reduced ejection fraction and systemic inflammation. The purpose of these trials is to determine whether new anti-inflammatory treatment strategies can lower the risk of worsening heart disease and related complications.

• Heart failure with systemic inflammation
• HFmrEF and HFpEF
• Evaluating prevention of cardiovascular events and symptom worsening
• Testing whether inflammation-targeted treatment can improve outcomes

These studies highlight a growing interest in the connection between inflammation and chronic heart disease.